Syntax Bio
PrivateLast Round
Series A
Jun 21, 2026
Total Funding Raised
$29.4M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Syntax Bio is a synthetic biology company that programs the next generation of stem cell-derived therapies and organoids using its proprietary CRISPR-based Cellgorithm platform.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, ML Platforms, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Syntax Bio Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Syntax Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 21, 2026 | ||||
| Series A | Sep 17, 2024 |
Key People
Founding team and executive leadership
Syntax Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LongGame Ventures | Series A |
| DCVC Bio | Series A |
| Mansueto Office | Series A |
| EGB Capital | Series A |
| Mayo Clinic Ventures | Series A |
| Draper Associates | Series A |
| Astellas Venture Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
$14M round with participation from DCVC Bio and Allegis Capital.
- Feb 1, 2026
Monthly visitors increased 36% MoM.
Syntax Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Syntax Bio's valuation, stock price, and market status.